当前位置: 首页 >> 检索结果
281. Clinical and cost-effectiveness of nurse-delivered sleep restriction therapy for insomnia in primary care (HABIT): a pragmatic, superiority, open-label, randomised controlled trial.
作者: Simon D Kyle.;A Niroshan Siriwardena.;Colin A Espie.;Yaling Yang.;Stavros Petrou.;Emma Ogburn.;Nargis Begum.;Leonie F Maurer.;Barbara Robinson.;Caroline Gardner.;Victoria Lee.;Stephanie Armstrong.;Julie Pattinson.;Sam Mort.;Eleanor Temple.;Victoria Harris.;Ly-Mee Yu.;Peter Bower.;Paul Aveyard.
来源: Lancet. 2023年402卷10406期975-987页
Insomnia is prevalent and distressing but access to the first-line treatment, cognitive behavioural therapy (CBT), is extremely limited. We aimed to assess the clinical and cost-effectiveness of sleep restriction therapy, a key component of CBT, which has the potential to be widely implemented.
282. Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial.
作者: Anurag Bhargava.;Madhavi Bhargava.;Ajay Meher.;Andrea Benedetti.;Banurekha Velayutham.;G Sai Teja.;Basilea Watson.;Ganesh Barik.;Rajeev Ranjan Pathak.;Ranjit Prasad.;Rakesh Dayal.;Adarsh Kibballi Madhukeshwar.;Vineet Chadha.;Madhukar Pai.;Rajendra Joshi.;Dick Menzies.;Soumya Swaminathan.
来源: Lancet. 2023年402卷10402期627-640页
In India, tuberculosis and undernutrition are syndemics with a high burden of tuberculosis coexisting with a high burden of undernutrition in patients and in the population. The aim of this study was to determine the effect of nutritional supplementation on tuberculosis incidence in household contacts of adults with microbiologically confirmed pulmonary tuberculosis.
283. Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
作者: Christopher W Ryan.;Catherine M Tangen.;Elisabeth I Heath.;Mark N Stein.;Maxwell V Meng.;Ajjai S Alva.;Sumanta K Pal.;Igor Puzanov.;Joseph I Clark.;Toni K Choueiri.;Neeraj Agarwal.;Robert G Uzzo.;Naomi B Haas.;Timothy W Synold.;Melissa Plets.;Ulka N Vaishampayan.;Brian M Shuch.;Ian M Thompson.;Primo N Lara.
来源: Lancet. 2023年402卷10407期1043-1051页
Patients undergoing resection of renal cell carcinoma are at risk of disease relapse. We evaluated the effectiveness of the mammalian target of rapamycin inhibitor everolimus administered after surgery.
284. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Patricia Pozo-Rosich.;Jessica Ailani.;Messoud Ashina.;Peter J Goadsby.;Richard B Lipton.;Uwe Reuter.;Hua Guo.;Brittany Schwefel.;Kaifeng Lu.;Ramesh Boinpally.;Rosa Miceli.;Rosa De Abreu Ferreira.;Emily McCusker.;Sung Yun Yu.;Lawrence Severt.;Michelle Finnegan.;Joel M Trugman.
来源: Lancet. 2023年402卷10404期775-785页
In this study, we aimed to evaluate the efficacy, safety, and tolerability of atogepant for the preventive treatment of chronic migraine.
285. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
作者: Shukui Qin.;Stephen L Chan.;Shanzhi Gu.;Yuxian Bai.;Zhenggang Ren.;Xiaoyan Lin.;Zhendong Chen.;Weidong Jia.;Yongdong Jin.;Yabing Guo.;Xiaohua Hu.;Zhiqiang Meng.;Jun Liang.;Ying Cheng.;Jianping Xiong.;Hong Ren.;Fang Yang.;Wei Li.;Yajin Chen.;Yong Zeng.;Alexander Sultanbaev.;Monika Pazgan-Simon.;Margaryta Pisetska.;Davide Melisi.;Dmitriy Ponomarenko.;Yurii Osypchuk.;Ivan Sinielnikov.;Tsai-Sheng Yang.;Xiao Liang.;Chunxia Chen.;Linna Wang.;Ann-Lii Cheng.;Ahmed Kaseb.;Arndt Vogel.; .
来源: Lancet. 2023年402卷10408期1133-1146页
Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-angiogenic therapy alone in advanced solid tumours, but not in hepatocellular carcinoma. Therefore, a clinical study was conducted to compare the efficacy and safety of the anti-PD-1 antibody camrelizumab plus the VEGFR2-targeted TKI rivoceranib (also known as apatinib) versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
286. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial.
作者: Frank R Lin.;James R Pike.;Marilyn S Albert.;Michelle Arnold.;Sheila Burgard.;Theresa Chisolm.;David Couper.;Jennifer A Deal.;Adele M Goman.;Nancy W Glynn.;Theresa Gmelin.;Lisa Gravens-Mueller.;Kathleen M Hayden.;Alison R Huang.;David Knopman.;Christine M Mitchell.;Thomas Mosley.;James S Pankow.;Nicholas S Reed.;Victoria Sanchez.;Jennifer A Schrack.;B Gwen Windham.;Josef Coresh.; .
来源: Lancet. 2023年402卷10404期786-797页
Hearing loss is associated with increased cognitive decline and incident dementia in older adults. We aimed to investigate whether a hearing intervention could reduce cognitive decline in cognitively healthy older adults with hearing loss.
287. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
作者: Joe Y Chang.;Steven H Lin.;Wenli Dong.;Zhongxing Liao.;Saumil J Gandhi.;Carl M Gay.;Jianjun Zhang.;Stephen G Chun.;Yasir Y Elamin.;Frank V Fossella.;George Blumenschein.;Tina Cascone.;Xiuning Le.;Jenny V Pozadzides.;Anne Tsao.;Vivek Verma.;James W Welsh.;Aileen B Chen.;Mehmet Altan.;Reza J Mehran.;Ara A Vaporciyan.;Stephen G Swisher.;Peter A Balter.;Junya Fujimoto.;Ignacio I Wistuba.;Lei Feng.;J Jack Lee.;John V Heymach.
来源: Lancet. 2023年402卷10405期871-881页
Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable early-stage non-small-cell lung cancer (NSCLC), but regional or distant relapses, or both, are common. Immunotherapy reduces recurrence and improves survival in people with stage III NSCLC after chemoradiotherapy, but its utility in stage I and II cases is unclear. We therefore conducted a randomised phase 2 trial of SABR alone compared with SABR with immunotherapy (I-SABR) for people with early-stage NSCLC.
288. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
作者: Jürgen C Becker.;Selma Ugurel.;Ulrike Leiter.;Friedegund Meier.;Ralf Gutzmer.;Sebastian Haferkamp.;Lisa Zimmer.;Elisabeth Livingstone.;Thomas K Eigentler.;Axel Hauschild.;Felix Kiecker.;Jessica C Hassel.;Peter Mohr.;Michael Fluck.;Ioannis Thomas.;Marlene Garzarolli.;Imke Grimmelmann.;Konstantin Drexler.;Alexandra N Spillner.;Sebastian Eckhardt.;Dirk Schadendorf.; .
来源: Lancet. 2023年402卷10404期798-808页
Merkel cell carcinoma (MCC) is an immunogenic but aggressive skin cancer. Even after complete resection and radiation, relapse rates are high. PD-1 and PD-L1 checkpoint inhibitors showed clinical benefit in advanced MCC. We aimed to assess efficacy and safety of adjuvant immune checkpoint inhibition in completely resected MCC (ie, a setting without an established systemic standard-of-care treatment).
289. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
作者: Athimalaipet V Ramanan.;Pierre Quartier.;Nami Okamoto.;Ivan Foeldvari.;Alberto Spindler.;Šárka Fingerhutová.;Jordi Antón.;Zhongkai Wang.;Gabriella Meszaros.;Joana Araújo.;Ran Liao.;Stuart Keller.;Hermine I Brunner.;Nicolino Ruperto.; .; .
来源: Lancet. 2023年402卷10401期555-570页
Juvenile idiopathic arthritis can be refractory to some or all treatment regimens, therefore new medications are needed to treat this population. This trial assessed the efficacy and safety of baricitinib, an oral Janus kinase 1/2-selective inhibitor, versus placebo in patients with juvenile idiopathic arthritis.
290. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
作者: Siow Ming Lee.;Christian Schulz.;Kumar Prabhash.;Dariusz Kowalski.;Aleksandra Szczesna.;Baohui Han.;Achim Rittmeyer.;Toby Talbot.;David Vicente.;Raffaele Califano.;Diego Cortinovis.;Anh Tuan Le.;Dingzhi Huang.;Geoffrey Liu.;Federico Cappuzzo.;Jessica Reyes Contreras.;Martin Reck.;Ramon Palmero.;Milena Perez Mak.;Youyou Hu.;Stefanie Morris.;Elen Höglander.;Mary Connors.;Alice M Biggane.;Hans Kristian Vollan.;Solange Peters.
来源: Lancet. 2023年402卷10400期451-463页
Despite immunotherapy advancements for patients with advanced or metastatic non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 and a median age of 65 years or younger. We aimed to compare the efficacy and safety of first-line atezolizumab monotherapy with single-agent chemotherapy in patients ineligible for platinum-based chemotherapy.
291. Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial.
作者: Alice Beardmore-Gray.;Nicola Vousden.;Paul T Seed.;Bellington Vwalika.;Sebastian Chinkoyo.;Victor Sichone.;Alexander B Kawimbe.;Umesh Charantimath.;Geetanjali Katageri.;Mrutyunjaya B Bellad.;Laxmikant Lokare.;Kasturi Donimath.;Shailaja Bidri.;Shivaprasad Goudar.;Jane Sandall.;Lucy C Chappell.;Andrew H Shennan.; .
来源: Lancet. 2023年402卷10399期386-396页
Pre-eclampsia is a leading cause of maternal and perinatal mortality. Evidence regarding interventions in a low-income or middle-income setting is scarce. We aimed to evaluate whether planned delivery between 34+ 0 and 36+ 6 weeks' gestation can reduce maternal mortality and morbidity without increasing perinatal complications in India and Zambia.
292. Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial.
作者: Caitlin M P Jones.;Richard O Day.;Bart W Koes.;Jane Latimer.;Chris G Maher.;Andrew J McLachlan.;Laurent Billot.;Sana Shan.;Chung-Wei Christine Lin.; .
来源: Lancet. 2023年402卷10398期304-312页
Opioid analgesics are commonly used for acute low back pain and neck pain, but supporting efficacy data are scarce. We aimed to investigate the efficacy and safety of a judicious short course of an opioid analgesic for acute low back pain and neck pain.
293. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
作者: Julio Rosenstock.;Juan Frias.;Ania M Jastreboff.;Yu Du.;Jitong Lou.;Sirel Gurbuz.;Melissa K Thomas.;Mark L Hartman.;Axel Haupt.;Zvonko Milicevic.;Tamer Coskun.
来源: Lancet. 2023年402卷10401期529-544页
According to current consensus guidelines for type 2 diabetes management, bodyweight management is as important as attaining glycaemic targets. Retatrutide, a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptors, showed clinically meaningful glucose-lowering and bodyweight-lowering efficacy in a phase 1 study. We aimed to examine the efficacy and safety of retatrutide in people with type 2 diabetes across a range of doses.
294. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
作者: Vanita R Aroda.;Jens Aberle.;Lars Bardtrum.;Erik Christiansen.;Filip K Knop.;Sanaz Gabery.;Sue D Pedersen.;John B Buse.
来源: Lancet. 2023年402卷10403期693-704页
Once-daily oral semaglutide is an effective type 2 diabetes treatment. We aimed to investigate a new formulation of oral semaglutide at higher investigational doses versus the approved 14 mg dose in adults with inadequately controlled type 2 diabetes.
295. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
作者: Filip K Knop.;Vanita R Aroda.;Ruben D do Vale.;Thomas Holst-Hansen.;Peter N Laursen.;Julio Rosenstock.;Domenica M Rubino.;W Timothy Garvey.; .
来源: Lancet. 2023年402卷10403期705-719页
We assessed the efficacy and safety of the oral glucagon-like peptide-1 analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of overweight or obesity in adults without type 2 diabetes.
296. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
作者: W Timothy Garvey.;Juan P Frias.;Ania M Jastreboff.;Carel W le Roux.;Naveed Sattar.;Diego Aizenberg.;Huzhang Mao.;Shuyu Zhang.;Nadia N Ahmad.;Mathijs C Bunck.;Imane Benabbad.;Xiaotian M Zhang.; .
来源: Lancet. 2023年402卷10402期613-626页
Weight reduction is essential for improving health outcomes in people with obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, versus placebo, for weight management in people living with obesity and type 2 diabetes.
297. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
作者: Juan P Frias.;Stanley Hsia.;Sarah Eyde.;Rong Liu.;Xiaosu Ma.;Manige Konig.;Christof Kazda.;Kieren J Mather.;Axel Haupt.;Edward Pratt.;Deborah Robins.
来源: Lancet. 2023年402卷10400期472-483页
Orforglipron, an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist, is in development for type 2 diabetes and obesity. We assessed the efficacy and safety of orforglipron versus placebo or dulaglutide in participants with type 2 diabetes.
298. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
作者: Juan P Frias.;Srikanth Deenadayalan.;Lars Erichsen.;Filip K Knop.;Ildiko Lingvay.;Stanislava Macura.;Chantal Mathieu.;Sue D Pedersen.;Melanie Davies.
来源: Lancet. 2023年402卷10403期720-730页
Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrilintide has weight-loss benefits; the impact on glycated haemoglobin (HbA1c) is unknown. This trial assessed the efficacy and safety of co-administered semaglutide with cagrilintide (CagriSema) in participants with type 2 diabetes.
299. High-dose dual-antibiotic loaded cement for hip hemiarthroplasty in the UK (WHiTE 8): a randomised controlled trial.
作者: Nickil R Agni.;Matthew L Costa.;Juul Achten.;Nicholas Peckham.;Susan J Dutton.;May Ee Png.;Mike R Reed.; .
来源: Lancet. 2023年402卷10397期196-202页
Hip fracture is the most common injury requiring treatment in hospital. Controversy exists regarding the use of antibiotic loaded bone cement in hip fractures treated with hemiarthroplasty. We aimed to compare the rate of deep surgical site infection in patients receiving high-dose dual-antibiotic loaded cement versus standard care single-antibiotic loaded cement.
300. Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial.
作者: Michael G Collins.;Magid A Fahim.;Elaine M Pascoe.;Carmel M Hawley.;David W Johnson.;Julie Varghese.;Laura E Hickey.;Philip A Clayton.;Kathryn B Dansie.;Rachael C McConnochie.;Liza A Vergara.;Charani Kiriwandeniya.;Donna Reidlinger.;Peter F Mount.;Laurence Weinberg.;Colin J McArthur.;P Toby Coates.;Zoltan H Endre.;David Goodman.;Kirsten Howard.;Martin Howell.;Jagadish S Jamboti.;John Kanellis.;Jerome M Laurence.;Wai H Lim.;Steven J McTaggart.;Philip J O'Connell.;Helen L Pilmore.;Germaine Wong.;Steven J Chadban.; .; .
来源: Lancet. 2023年402卷10396期105-117页
Delayed graft function (DGF) is a major adverse complication of deceased donor kidney transplantation. Intravenous fluids are routinely given to patients receiving a transplant to maintain intravascular volume and optimise graft function. Saline (0·9% sodium chloride) is widely used but might increase the risk of DGF due to its high chloride content. We aimed to test our hypothesis that using a balanced low-chloride crystalloid solution (Plasma-Lyte 148) instead of saline would reduce the incidence of DGF.
|